279 related articles for article (PubMed ID: 31179753)
1. Impact of extremely low-frequency electromagnetic field (100 Hz, 100 G) exposure on human glioblastoma U87 cells during Temozolomide administration.
Ahmadi-Zeidabadi M; Akbarnejad Z; Esmaeeli M; Masoumi-Ardakani Y; Mohammadipoor-Ghasemabad L; Eskandary H
Electromagn Biol Med; 2019; 38(3):198-209. PubMed ID: 31179753
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxicity of temozolomide on human glioblastoma cells is enhanced by the concomitant exposure to an extremely low-frequency electromagnetic field (100Hz, 100G).
Akbarnejad Z; Eskandary H; Dini L; Vergallo C; Nematollahi-Mahani SN; Farsinejad A; Abadi MFS; Ahmadi M
Biomed Pharmacother; 2017 Aug; 92():254-264. PubMed ID: 28551545
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxicity of carboplatin on human glioblastoma cells is reduced by the concomitant exposure to an extremely low-frequency electromagnetic field (50 Hz, 70 G).
Amiri M; Basiri M; Eskandary H; Akbarnejad Z; Esmaeeli M; Masoumi-Ardakani Y; Ahmadi-Zeidabadi M
Electromagn Biol Med; 2018; 37(3):138-145. PubMed ID: 29846098
[TBL] [Abstract][Full Text] [Related]
4. Exposure to Low-Frequency Radiation Changes the Expression of Nestin, VEGF, BCRP and Apoptosis Markers During Glioma Treatment Strategy: An
Amirinejad M; Eftekhar-Vaghefi SH; Nematollahi Mahani SN; Salari M; Yahyapour R; Ahmadi-Zeidabadi M
Curr Radiopharm; 2024; 17(1):55-67. PubMed ID: 38817005
[TBL] [Abstract][Full Text] [Related]
5. Effects of extremely low-frequency pulsed electromagnetic fields (ELF-PEMFs) on glioblastoma cells (U87).
Akbarnejad Z; Eskandary H; Vergallo C; Nematollahi-Mahani SN; Dini L; Darvishzadeh-Mahani F; Ahmadi M
Electromagn Biol Med; 2017; 36(3):238-247. PubMed ID: 27874284
[TBL] [Abstract][Full Text] [Related]
6. Comparative Study of Extremely Low-Frequency Electromagnetic Field, Radiation, and Temozolomide Administration in Spheroid and Monolayer Forms of the Glioblastoma Cell Line (T98).
Yahyapour R; Khoei S; Kordestani Z; Larizadeh MH; Jomehzadeh A; Amirinejad M; Ahmadi-Zeidabadi M
Curr Radiopharm; 2023; 16(2):123-132. PubMed ID: 36503396
[TBL] [Abstract][Full Text] [Related]
7. Pulsed and Discontinuous Electromagnetic Field Exposure Decreases Temozolomide Resistance in Glioblastoma by Modulating the Expression of O
Dehghani-Soltani S; Eftekhar-Vaghefi SH; Babaee A; Basiri M; Mohammadipoor-Ghasemabad L; Vosough P; Ahmadi-Zeidabadi M
Cancer Biother Radiopharm; 2021 Sep; 36(7):579-587. PubMed ID: 32644826
[No Abstract] [Full Text] [Related]
8. Effect of the STAT3 inhibitor STX-0119 on the proliferation of a temozolomide-resistant glioblastoma cell line.
Ashizawa T; Akiyama Y; Miyata H; Iizuka A; Komiyama M; Kume A; Omiya M; Sugino T; Asai A; Hayashi N; Mitsuya K; Nakasu Y; Yamaguchi K
Int J Oncol; 2014 Jul; 45(1):411-8. PubMed ID: 24820265
[TBL] [Abstract][Full Text] [Related]
9. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation.
Liang H; Chen Z; Sun L
Mol Carcinog; 2019 Aug; 58(8):1502-1511. PubMed ID: 31045274
[TBL] [Abstract][Full Text] [Related]
11. Isofuranodiene synergizes with temozolomide in inducing glioma cells death.
Brunetti A; Marinelli O; Morelli MB; Iannarelli R; Amantini C; Russotti D; Santoni G; Maggi F; Nabissi M
Phytomedicine; 2019 Jan; 52():51-59. PubMed ID: 30599912
[TBL] [Abstract][Full Text] [Related]
12. GADD45A plays a protective role against temozolomide treatment in glioblastoma cells.
Wang HH; Chang TY; Lin WC; Wei KC; Shin JW
Sci Rep; 2017 Aug; 7(1):8814. PubMed ID: 28821714
[TBL] [Abstract][Full Text] [Related]
13. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
[TBL] [Abstract][Full Text] [Related]
14. Enrichment of superoxide dismutase 2 in glioblastoma confers to acquisition of temozolomide resistance that is associated with tumor-initiating cell subsets.
Chien CH; Chuang JY; Yang ST; Yang WB; Chen PY; Hsu TI; Huang CY; Lo WL; Yang KY; Liu MS; Chu JM; Chung PH; Liu JJ; Chou SW; Chen SH; Chang KY
J Biomed Sci; 2019 Oct; 26(1):77. PubMed ID: 31629402
[TBL] [Abstract][Full Text] [Related]
15. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
[TBL] [Abstract][Full Text] [Related]
16. Targeting Aurora kinase B attenuates chemoresistance in glioblastoma via a synergistic manner with temozolomide.
Alafate W; Wang M; Zuo J; Wu W; Sun L; Liu C; Xie W; Wang J
Pathol Res Pract; 2019 Nov; 215(11):152617. PubMed ID: 31563286
[TBL] [Abstract][Full Text] [Related]
17. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
[TBL] [Abstract][Full Text] [Related]
18. miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.
Wei J; Qi X; Zhan Q; Zhou D; Yan Q; Wang Y; Mo L; Wan Y; Xie D; Xie J; Yang S
Biomed Pharmacother; 2015 Apr; 71():112-8. PubMed ID: 25960225
[TBL] [Abstract][Full Text] [Related]
19. Simvastatin Induces Unfolded Protein Response and Enhances Temozolomide-Induced Cell Death in Glioblastoma Cells.
Dastghaib S; Shojaei S; Mostafavi-Pour Z; Sharma P; Patterson JB; Samali A; Mokarram P; Ghavami S
Cells; 2020 Oct; 9(11):. PubMed ID: 33105603
[TBL] [Abstract][Full Text] [Related]
20. YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line.
Akiyama Y; Ashizawa T; Komiyama M; Miyata H; Oshita C; Omiya M; Iizuka A; Kume A; Sugino T; Hayashi N; Mitsuya K; Nakasu Y; Yamaguchi K
Oncol Rep; 2014 Jul; 32(1):159-66. PubMed ID: 24842123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
